drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous BCMA-directed CAR T-cell therapy; a single infusion of gene-modified T cells that recognize BCMA and trigger T-cell activation and cytotoxic elimination of myeloma cells.
nci_thesaurus_concept_id
C185123
nci_thesaurus_preferred_term
Equecabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) with a fully human single chain variable fragment (scFv) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, equecabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells, and plays a key role in plasma cell proliferation and survival.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transduced with a lentiviral vector to express a BCMA-specific chimeric antigen receptor. Binding to BCMA on malignant plasma cells triggers T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic elimination of BCMA-expressing myeloma cells.
drug_name
Equecabtagene autoleucel
nct_id_drug_ref
NCT06464991